Newsroom

News

For many diseases, the tools of medicine are reaching their limits. CRISPR technologies open new avenues for diagnostics and therapies, although the natural source of CRISPR remains largely untapped. Scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg, a joint venture of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Julius Maximilian University (JMU) Würzburg, now demonstrate a new way to study CRISPR systems that can accelerate their conversion into tools. Their approach was published today in the journal Molecular Cell.

24.02.2022

HIRI

News

Liver cancer is the third most common cause of cancer-related deaths worldwide. So far, the treatment options for two types of liver cancer, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), have been inadequate, while the number of new cases has been rising. A study by researchers at the Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI) now offers hope. A vaccine based on a highly attenuated infectious agent called Listeria monocytogenes proved to be safe and effective protection in premalignant and malignant liver diseases in preclinical mouse models.

18.02.2022

HZI Campus

News

An international research team from TWINCORE - Centre for Experimental and Clinical Infection Research, a joint facility of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Hannover Medical School, describes the dual effect of the endogenous substance itaconic acid, which is both antiviral and anti-inflammatory. Their study, which has now appeared in the journal PLoS Pathogens, opens up perspectives for possible therapeutic applications of itaconic acid against severe courses of disease in viral infections.

17.02.2022

HZI Campus

TWINCORE

Fruchtkörper von Myxobakterien unter dem Lichtmikroskop

News

Pharma-backed incubator INCATE selected the HZI start-up project Myxobiotics as one of the first start-ups to get support. Myxobiotics develops a new class of antibiotics against Acinetobacter baumannii, which causes severe, difficult-to-treat respiratory infections. Myxobiotics’ approach is based on a new class of natural compounds (cystobactamids) discovered and developed as antibacterial agents by Prof Rolf Müller and Prof Mark Brönstrup and their teams at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Helmholtz Centre for Infection Research (HZI), together with Dr Thomas Hesterkamp and Evotec. The HIPS is a site of the HZI in collaboration with Saarland University.

04.02.2022

HZI Campus

HIPS

News

The Minister President of Lower Saxony, Stephan Weil, visited the Helmholtz Centre for Infection Research (HZI) today, 4 February 2022. The visit focused on the current challenges and innovative approaches, especially in combating the SARS-CoV-2 pandemic, and the future development of infection research in Lower Saxony. He also delivered a message of thanks to the scientists at the research centre in Braunschweig.

04.02.2022

HZI Campus

News

Viruses are mostly encountered as pathogens. However, virus-based vaccination platforms can also help to provide protection from different diseases. In a mouse model, researchers from the Helmholtz Centre for Infection Research (HZI) in Braunschweig together with national and international partners including the German Center for Infection Research (DZIF), the German Primate Center – Leibniz Institute for Primate Research (DPZ), the Technische Universität Braunschweig and the University of Rijeka, Croatia, have developed a novel cytomegalovirus-based vaccine against different respiratory viruses. A single dose of the vaccine that consists of a cytomegalovirus that incorporates genes from coronavirus or influenza A efficiently protected mice from the respiratory infections. The results on the vaccine candidate, which is not yet market-ready, were published in the journal Cellular & Molecular Immunity.

17.01.2022

HZI Campus

Back to the first page
...
48
49
50
51
...
151

HZI in the media

Medicine (CiiM), which is a joint institution of the Helmholtz Center for Infection Research (HZI) and Hannover Medical School (MHH). Using

29.01.2026

Medical Xpress

... stumpfen ab“, erklärt Marc Brönstrup vom Helmholtz-Zentrum für Infektionsforschung in Braunschweig. Neue Antibiotika sind dringend ...

27.01.2026

Tvinfo.de

entered an exclusive research partnership with the Helmholtz Centre for Infection Research’s HIPS institute to investigate how the skin

22.01.2026

Simply Wall St News

... der MHH, des TWINCORE Hannover und des Helmholtz-Instituts für Infektionsforschung (HZI). Ihre wissenschaftliche Expertise ...

21.01.2026

hannover.de

... auch Teil des Ecoversity-Programms der Technischen Universität Braunschweig.

GN De hlth| Source | domain www.helmholtz-hzi.

20.01.2026

Die heutigen Nachrichten

... validierte Daten der MHH und des Helmholtz-Zentrum für Infektionsforschung (HZI), die zeitnah in Fachjournalen veröffentlichet ...

19.01.2026

wallstreet:online

institutions, including Hannover Medical School and the Helmholtz Centre for Infection Research in Germany, the University of Duisburg Essen

18.01.2026

Thailandmedical

Lange , Kommissarische Leiterin der Abteilung Epidemiologie am Helmholtz-Zentrum für Infektionsforschung (HZI), Braunschweig, gegenüber dem

16.01.2026

Medscape

... maßgeblich vorantreiben. In Zusammenarbeit mit dem Braunschweiger Helmholtz-Zentrum für Infektionsforschung (HZI) und der Utah State ...

16.01.2026

IT Boltwise

... Deutschen Zentrum für Neurodegenerative Erkrankungen, am Helmholtz-Zentrum für Infektionsforschung und am Max-Delbrück-Centrum für ...

16.01.2026

Handelsblatt

Das interdisziplinäre Team aus TWINCORE , Helmholtz Zentrum für Infektionsforschung (HZI) und der Medizinischen Hochschule Hannover ( ...

15.01.2026

Arzt & Wirtschaft

Manche fordern Placebo-kontrollierte Vergleiche von Geimpften und Ungeimpften, um die Sicherheit der Masern-Impfung zu testen. ...

15.01.2026

BR Bayerischer Rundfunk

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.